Management of epidermal growth factor receptor inhibitor-associated rash: A systematic review

Journal of Community and Supportive Oncology

Volumn 14, Issue 1, 2016, Pages 21-28

  Brown, Jacqueline ^a   Su, Yun ^b   Nellesen, Dave ^c   Shankar, Pallavi ^c   Mayo, Carlos ^d  

^a ELI LILLY AND COMPANY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c ANALYSIS GROUP   (United States)

^d ImClone Systems   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BENZOYL PEROXIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; RETINOID; SALICYLIC ACID; VITAMIN K GROUP;

CLINICAL PRACTICE; DISEASE SEVERITY; DRUG ERUPTION; HUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

EID: 84962091067     PISSN: 23307749     EISSN: None     Source Type: Journal    
DOI: 10.12788/jcso.0193     Document Type: Review

References (53)

1. Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event-specifc grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010;18:509-522.
2. Potthof K, Hofheinz R, Hassel JC, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2011;22:524-535.
3. Lacouture M, Anadkat M, Bensadoun RJ, et al. MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079-1095.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
5. Moore MJ, Goldstein D, Hamm J, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
6. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance geftinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26:2450-2456.
7. Peeters M, Siena S, Van Cutsem E et al. Association of progressionfree survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer. 2009;115:1544-1554.
8. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373:1525-1531.
9. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563-572.
10. Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncol (Williston Park). 2007;21:34-36.
11. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040-2048.
12. Cascinu S, Berardi R, Labianca R, et al. Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 2008;9:39-44.
13. Okines AF, Ashley SE, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-fnding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol. 2010;28:3945-3950.
14. Bokemeyer C, Bondarenko I, A. Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the frst-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-671. Brown et al
15. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
16. Borner M, Koeberle D, Von MR, et al. Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in frst-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol. 2008;19:1288-1292.
17. Bukowski RM, Kabbinavar FF, Figlin RA et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007;25:4536-4541.
18. Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as frst-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol. 2007;25:5777-5784.
19. Cristofanilli M, Valero V, Mangalik A, et al. Phase II, randomized trial to compare anastrozole combined with geftinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010;16:1904-1914.
20. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545-1552.
21. Guarneri V, Frassoldati A, Ficarra G, et al. Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- geftinib with biomarker evaluation in operable breast cancer. Breast Cancer Res Treat. 2008;110:127-134.
22. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and frst-line taxane/ carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010;28:911-917.
23. Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as frst-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:5080-5087.
24. Tsuboi M, Kato H, Nagai K et al. Geftinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small-cell lung cancer. Anticancer Drugs. 2005;16:1123-1128.
25. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-1664.
26. Iressa [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2004.
27. Tarceva [package insert]. Farmingdale, NY: OSI Pharmaceuticals, LLC; 2012.
28. Erbitux [package insert]. Branchburg, NJ: ImClone LLC; 2013.
29. Vectibix [package insert]. Tousand Oaks, CA: Amgen Inc; 2013.
30. Moher D, Liberati A, Tetzlaf J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
31. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351-1357.
32. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113:847-853.
33. Scope A, Agero AL, Dusza SW, et al. Randomized doubleblind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25:5390-5396.
34. Pinto C, Barone C, Martoni A, et al. Vitamin K1 cream in the management of skin rash during anti-EGFR monoclonal antibody (mAb) treatment in patients with metastatic cancer: First analysis of an observational Italian study. J Clin Oncol. 2011;29:S594.
35. de Noronha e Menezes NM, Lima R, Moreira A, et al. Description and management of cutaneous side efects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients. Eur J Dermatol. 2009:19:248-251.
36. Manganoni AM, Farisoglio C, Ferrari V, et al. Multidisciplinary team-working indicators of good practice in the clinical management of EGFR-inhibitor dermatologic toxicities. Ann Surg Oncol. 2009;16:224-225.
37. Racca P, Fanchini L, Caliendo V, et al. Efcacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer. 2008;7:48-54.
38. Roé E, Garcia Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A. Description and management of cutaneous side efects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol. 2006;55:429-437.
39. Adams DH, Nutt T. A case report and discussion of cetuximabinduced folliculitis. Am J Clin Dermatol. 2006;7:333-336.
40. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf. 2007;6:175-182.
41. Duvic M. EGFR inhibitor-associated acneiform folliculitis: assessment and management. Am J Clin Dermatol. 2008;9:285-294.
42. Wong SF, Lindgren A, Mummaneni M, et al. A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors. J Support Oncol. 2010;8:202-208.
43. Alexandrescu DT, Kaufman LC and Dasanu CA. Treatment of epidermal growth factor-induced rash with colloidal oatmeal extract: An extended treatment follow-up. J Invest Derm. 2009;129(Suppl. 1s):346.
44. Eng C. Toxic efects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol. 2009;6:207-218.
45. Pinto C, Barone CA, Girolomoni G, et al. European Society of Medical Oncology. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. 2011;16:228-238.
46. Ouwerkerk J, Boers-Doets C. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs. 2010;14:337-349.
47. Burtness B, Anadkat, M, Basti, S, et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw. 2009;7:S5-S21; quiz S22-S24.
48. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-265.
49. Tatcher N, Nicolson M, Groves RW, et al. Expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK. Oncologist. 2009;14:840-847.
50. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425-1433.
51. Lynch TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007;12:610-621.
52. Chou LS, Garey J, Oishi K, Kim E. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. Clin Lung Cancer. 2006;8:S15-S22.
53. Rhee J, Oishi K, Garey J, Kim E. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clin Colorectal Cancer. 2005;5:S101-S106.